2. Academic Validation
  3. Tetrandrine inhibits RANKL-induced osteoclastogenesis by promoting the degradation of TRAIL

Tetrandrine inhibits RANKL-induced osteoclastogenesis by promoting the degradation of TRAIL

  • Mol Med. 2022 Nov 26;28(1):141. doi: 10.1186/s10020-022-00568-4.
Jiarui Li # 1,  Xiang Li # 1,  Shengji Zhou # 1,  Yuxin Wang 1,  Yang Lu 1,  Quan Wang 2,  Fengchao Zhao 3
Affiliations

Affiliations

  • 1 Department of Orthopaedic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, No.79 Qingchun Road, Hangzhou, 310003, People's Republic of China.
  • 2 Department of Orthopaedic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, No.79 Qingchun Road, Hangzhou, 310003, People's Republic of China. docwangquan@zju.edu.cn.
  • 3 Department of Orthopaedic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, No.79 Qingchun Road, Hangzhou, 310003, People's Republic of China. zhaofengchao@zju.edu.cn.
  • # Contributed equally.
PMID: 36435772 DOI: 10.1186/s10020-022-00568-4
Abstract

Background: Tetrandrine, a bisbenzylisoquinoline (BBI) alkaloid extracted from Stephania tetrandra (S. Moore), and is widely used in several diseases such as tuberculosis, hyperglycemia, malaria, and tumors. Tetrandrine was recently shown to prevent bone loss in ovariectomized mice. However, the specific mechanism underlying osteoclastogenesis inhibition remains unclear.

Methods: Tetrandrine's cytotoxicity to cells was determined using the Cell Counting Kit-8 assay. Tartrate-resistant Acid Phosphatase staining, immunofluorescence and bone resorption assay were performed to evaluate osteoclasts' differentiation and absorption capacity. The bone-forming capacity was assessed using Alkaline Phosphatase and Alizarin red S staining. qPCR and Western blotting were applied to assess the related genes and protein expression. Tetrandrine's impact on TRAIL was demonstrated through a co-immunoprecipitation assay. Animal experiments were performed for the detection of the therapeutic effect of Tetrandrine on osteoporosis.

Results: Tetrandrine attenuated RANKL-induced osteoclastogenesis and decreased the related gene expression. The co-immunoprecipitation assay revealed that Tetrandrine administration accelerated the ubiquitination of TNF-related apoptosis-inducing ligand (TRAIL), which was subsequently degraded. Moreover, TRAIL overexpression was found to partially reverse the Tetrandrine-induced inhibition of osteoclastogenesis. Meanwhile, Tetrandrine significantly inhibited the phosphorylation of p38, p65, JNK, IKBα and IKKα/β, while the TRAIL overexpression weakened this effect. In addition, Tetrandrine promoted osteogenesis and inhibited the TRAIL expression in osteoblasts. Tetrandrine consistently improved bone destruction by stimulating bone formation and inhibiting bone resorption in an OVX-induced mouse model.

Conclusion: Tetrandrine inhibits RANKL-induced osteoclastogenesis by promoting TRAIL degradation and promotes osteoblast differentiation, suggesting its potential in antiosteopenia pharmacotherapy.

Keywords

OVX; Osteoclastogenesis; RANKL; TRAIL; Tetrandrine.

Figures
Products